Prompt intervention for severe aortic stenosis patients demonstrates lower healthcare costs, improved clinical outcomes

Paris--(business wire)--edwards lifesciences (nyse: ew) today announced new economic and clinical evidence on severe aortic stenosis (as) presented as a late-breaking clinical trial at europcr 2025, further contributing to the extensive body of research on this disease. the results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outco.
EW Ratings Summary
EW Quant Ranking